Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
SEC Accession No. 0001213900-25-045399
Filing Date
2025-05-19
Accepted
2025-05-19 16:10:10
Documents
1
Period of Report
2025-05-14

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT marketforms-69540.html 4/A  
1 PRIMARY DOCUMENT marketforms-69540.xml 4/A 3906
  Complete submission text file 0001213900-25-045399.txt   5567
Mailing Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010 646-844-0337
Protara Therapeutics, Inc. (Issuer) CIK: 0001359931 (see all company filings)

EIN.: 204580525 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 860 WASHINGTON STREET 3RD FLOOR NEW YORK NY 10014
Business Address
Levy Richard S (Reporting) CIK: 0001454983 (see all company filings)

Type: 4/A | Act: 34 | File No.: 001-36694 | Film No.: 25963993